Nexilico Scales to 1.5 Million Microbiome Simulations and 40 Billion Metabolic Calculations

Danville, CA – July 7, 2025 – Nexilico, a leader in computational microbiome engineering, today announced that it has successfully scaled in silico microbiome simulations using its massively parallel microbiome digital twin platform - completing over 1.5 million virtual experiments and simulating more than 40 billion metabolic calculations. This achievement sets a new benchmark for scale, resolution, and speed in microbiome research.

Built on a foundation of mathematical, biophysical, and systems biology algorithms, Nexilico’s digital twin platform models the dynamic behavior of microbial communities under a wide range of perturbations. Each simulation captures interactions across thousands of metabolic features and tracks how microbial strains respond to changes over time. This high-throughput, mechanistic modeling approach has produced the largest virtual microbiome dataset to date, enabling deep, systems-level insights into microbial ecosystem dynamics.

This milestone was made possible through a combination of advanced software engineering, high-performance computing, and cloud-native infrastructure. Nexilico’s ability to operate at this scale was further supported by the AWS Activate, the NVIDIA Inception Program, and Google for Startups Cloud Program, which provided key infrastructure and technical resources.

“This milestone isn’t just about scale; it’s about capability,” said Mohammad Soheilypour, CEO of Nexilico. “We are now able to virtualize microbiome experimentation at a level never before possible, opening the door to faster, deeper exploration of microbiome-driven interventions.”

The resulting dataset provides an unprecedented view of microbial community behavior in response to specific strain perturbations and candidate therapeutic designs. By virtualizing these experiments, Nexilico enables faster, more cost-effective target and drug discovery, dramatically reducing the reliance on early-stage trial-and-error laboratory studies. This milestone marks the first phase of Nexilico’s broader mission to harness AI and digital twins to accelerate the development of microbiome-targeted therapeutics at population scale.

About Nexilico 

Nexilico is a biotech company focused on precision microbiome engineering through its innovative, modality-agnostic AI-driven discovery platform. Powered by its proprietary microbiome digital twin technology, Nexilico’s platform enables microbiome precision medicine and drives the development of diverse therapeutic strategies across a range of diseases. As a pioneer in next generation of in silico microbiome technologies, Nexilico is unlocking the full potential of the microbiome to address complex health challenges. To learn more about Nexilico’s mission to revolutionize microbiome engineering with AI, please visit us at http://www.nexilico.com/